Foreseeable Boost for Biotechnology
This week's Nasdaq Corporate Solutions Advisory Services commentary features Joe Rosenberg, healthcare and biotechnology specialist, delivering his outlook for the biotechnology sector in 2015:
- Accommodating regulatory environment - the FDA approved 41 new drugs during 2014, the largest number of yearly approvals in at least a decade.
- 2015 promises to be a big year for M&A - companies will seek to expand their portfolios of marketed drugs, grow their R&D pipelines, and complement existing businesses.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.